Clinical Trial

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-08-28; most recent amendment 2025-11-17.
Status change: Recruiting → Active, Not Recruiting 2020-12-30
Status change: Not Yet Recruiting → Recruiting 2020-10-06
Trial Details
NCT Number NCT04537156
Lead Sponsor Xiamen University
Collaborators: Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Conditions Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata
Enrollment 9,327 participants
Start Date 2020-09-05
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-21